# 바이오스페이스 일일 뉴스 리포트 - 2025년 12월 13일


## 주요 헤드라인

1. **‘Au Revoir TIGIT’ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/au-revoir-tigit-gilead-arcus-cut-gastro-cancer-drug-after-late-stage-failure>

2. **‘Au Revoir TIGIT’ (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/au-revoir-tigit-gilead-arcus-cut-gastro-cancer-drug-after-late-stage-failure>

3. **CDC Highlights Efficacy of COVID-19 Shots in Kids Amid FDA Probe of Alleged Deaths (#뉴스)**
   - Article content not available
   <https://www.biospace.com/drug-development/cdc-highlights-efficacy-of-covid-19-shots-in-kids-amid-fda-probe-of-alleged-deaths>

4. **Absence of Bureaucracy at FDA Is Shooting Pharma in the Foot (#뉴스)**
   - Article content not available
   <https://www.biospace.com/policy/absence-of-bureaucracy-at-fda-is-shooting-pharma-in-the-foot>

5. **Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/pfizer-is-not-a-done-dealmaker-after-metsera-buy-with-6b-more-to-spend>

6. **Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/pfizer-is-not-a-done-dealmaker-after-metsera-buy-with-6b-more-to-spend>

7. **Japanese Pharmas Looking Beyond Borders for M&A to US, EU (#뉴스)**
   - Article content not available
   <https://www.biospace.com/business/japanese-pharmas-looking-beyond-borders-for-m-a-to-us-eu>


---
*2025년 12월 13일 바이오스페이스 뉴스 피드에서 생성된 리포트*